SOUTH SAN FRANCISCO, Calif., Jan. 12, 2015 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX) announced today the closing of its public offering of 3,829,944 shares of its common stock, which includes 419,994 shares sold upon the partial exercise of the underwriters' option to purchase additional shares, resulting in aggregate gross proceeds of $84.3 million, before underwriting discounts and commissions, structuring fees and expenses.
Citigroup, Leerink Partners and Wells Fargo Securities are acting as joint book-running managers for the offering. Guggenheim Securities and Oppenheimer & Co. are acting as co-managers.
The securities described above were offered pursuant to a "shelf" registration statement previously filed and declared effective by the Securities and Exchange Commission (SEC). The offering was made only by means of a prospectus supplement and accompanying base prospectus, copies of which may be obtained from: Citigroup Global Markets Inc., c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY 11717, telephone: (800) 831-9146, email: prospectus@citi.com; Leerink Partners LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, telephone: (800) 808-7525, email: syndicate@Leerink.com; or Wells Fargo Securities, LLC, Attention: Equity Syndicate Department, 375 Park Avenue, New York, New York, 10152, telephone: (800) 326-5897, email: cmclientsupport@wellsfargo.com. An electronic copy of the prospectus supplement and accompanying base prospectus relating to the offering are available on the website of the SEC at www.sec.gov.
This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.